Jon Napitupulu

BioVersys reported a busy first half: a successful end-of-Phase two meeting with the FDA for BV100 in ventilator-associated bacterial...

Scancell has reported robust Phase 2 data for its next-generation DNA vaccine iSCIB1+ in advanced melanoma, confirmed plans to...

BioVersys has set a 2025 start for a global Phase 3 program of BV100 in ventilator- and hospital-acquired bacterial...

NanoNewron has secured a $2.5 million NIH STTR Phase 2 grant to advance NN-840, a blood–brain barrier–penetrant TNF-alpha inhibitor...

BioVersys has tightened its execution across three antibacterial programs while shoring up its balance sheet. The company aligned with...

Maze Therapeutics has appointed Misbah Tahir as chief financial officer, adding a capital markets veteran ahead of a dense...

BioNTX has named eight companies to its 2025 Rising Stars cohort, to be showcased at the 11th iC³ Life...

Stratus Therapeutics has added Nobel laureate Ardem Patapoutian to its Scientific Advisory Board as it advances ST-101, an allogeneic,...

Merakris Therapeutics has enrolled the 30th patient in its Expanded Access Program for MTX-001, an injectable, cell-free amniotic fluid–derived...

BioNTX’s IC³ Life Science & Healthcare Innovation Summit will put federal and alternative R&D capital under the microscope in...